Obicetrapib

Obicetrapib is an experimental CETP inhibitor that is intended to treat dyslipidemia. In a clinical trial, as an add-on to statins, compared with placebo, it decreased concentrations of LDL-C (by up to 51%), apolipoprotein B (by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) (by up to 44%), and increased HDL-C concentration (by up to 165%).^[1][2] As of 2023, it is in a Phase III trial.^[3]

Obicetrapib

Clinical data
Other names	TA-8995; AMG-899
Legal status
Legal status	Investigational
Identifiers
IUPAC name 4-[2-[[3,5-bis(trifluoromethyl)phenyl]methyl-[(2R,4S)-1-ethoxycarbonyl-2-ethyl-6-(trifluoromethyl)-3,4-dihydro-2H-quinolin-4-yl]amino]pyrimidin-5-yl]oxybutanoic acid
CAS Number	866399-87-3
PubChem CID	11498596
DrugBank	DB14890
ChemSpider	9673402
UNII	8O74K609HN
KEGG	D12900
ChEMBL	ChEMBL3785197
Chemical and physical data
Formula	C32H31F9N4O5
Molar mass	722.609 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC[C@@H]1C[C@@H](C2=C(N1C(=O)OCC)C=CC(=C2)C(F)(F)F)N(CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F)C4=NC=C(C=N4)OCCCC(=O)O
InChI InChI=1S/C32H31F9N4O5/c1-3-22-14-26(24-13-19(30(33,34)35)7-8-25(24)45(22)29(48)49-4-2)44(28-42-15-23(16-43-28)50-9-5-6-27(46)47)17-18-10-20(31(36,37)38)12-21(11-18)32(39,40)41/h7-8,10-13,15-16,22,26H,3-6,9,14,17H2,1-2H3,(H,46,47)/t22-,26+/m1/s1 Key:NRWORBQAOQVYBJ-GJZUVCINSA-N

History

Obicetrapib was initially developed by Amgen as AMG-899 and was abandoned in 2017.^[4] In 2020, Amgen licensed the drug to NewAmsterdam Pharma.^[5]